Neuroscience
Biogen and F.D.A. Issue Drug Warning
By ANDREW POLLACK
The New York Times
Published: March 17, 2005
Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said yesterday.
The warning was another blow, though probably only a glancing one, to Biogen, which is already reeling from the halt in sales of its other multiple sclerosis drug, Tysabri, which was linked to a rare brain infection.
In a related development, GlaxoSmithKline said yesterday that the F.D.A. had ordered it to halt a trial of its multiple sclerosis drug, which works in a similar way as Tysabri.
A Glaxo spokesman said the company understood that a halt was made as a precaution in trials of all drugs in the same class as Tysabri. A spokeswoman for the F.D.A. said the agency could not comment because of confidentiality about clinical trials.
[ ... Read the full article ... ] (free registration required)
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:A fourth death may be tied to Biogen's MS drug Finding could be blow to marketplace hopes By Jeffrey Krasner, Boston Globe Staff June 2, 2005 Biogen Idec Inc. has told the Food and Drug Administration that a fourth...
- Business World: Tysabri (natalizumab) And Biogen Idec
From today's Boston Globe: Biogen Idec's top lawyer quits amid investigation By Jeffrey Krasner The Boston Globe March 10, 2005 Thomas J. Bucknum, Biogen Idec's longtime top lawyer, resigned suddenly yesterday amid an inquiry by the Securities...
- Tysabri (natalizumab): An Additional Case
Rare Infection Is Confirmed in 2nd Patient on M.S. Drug By ANDREW POLLACK The New York Times Published: March 4, 2005 The makers of the multiple sclerosis drug Tysabri said yesterday that a second patient who used the drug had been confirmed to be suffering...
Neuroscience
More M.S. Drug Woes: Avonex and 683699
Biogen and F.D.A. Issue Drug Warning
By ANDREW POLLACK
The New York Times
Published: March 17, 2005
Biogen Idec's multiple sclerosis drug Avonex might cause severe liver damage in rare cases, the company and the Food and Drug Administration said yesterday.
The warning was another blow, though probably only a glancing one, to Biogen, which is already reeling from the halt in sales of its other multiple sclerosis drug, Tysabri, which was linked to a rare brain infection.
In a related development, GlaxoSmithKline said yesterday that the F.D.A. had ordered it to halt a trial of its multiple sclerosis drug, which works in a similar way as Tysabri.
A Glaxo spokesman said the company understood that a halt was made as a precaution in trials of all drugs in the same class as Tysabri. A spokeswoman for the F.D.A. said the agency could not comment because of confidentiality about clinical trials.
[ ... Read the full article ... ] (free registration required)
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab)
From today's Boston Globe:A fourth death may be tied to Biogen's MS drug Finding could be blow to marketplace hopes By Jeffrey Krasner, Boston Globe Staff June 2, 2005 Biogen Idec Inc. has told the Food and Drug Administration that a fourth...
- Business World: Tysabri (natalizumab) And Biogen Idec
From today's Boston Globe: Biogen Idec's top lawyer quits amid investigation By Jeffrey Krasner The Boston Globe March 10, 2005 Thomas J. Bucknum, Biogen Idec's longtime top lawyer, resigned suddenly yesterday amid an inquiry by the Securities...
- Tysabri (natalizumab): An Additional Case
Rare Infection Is Confirmed in 2nd Patient on M.S. Drug By ANDREW POLLACK The New York Times Published: March 4, 2005 The makers of the multiple sclerosis drug Tysabri said yesterday that a second patient who used the drug had been confirmed to be suffering...